GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.

Trial Details

NCT ID
NCT06636123
Phase
PHASE1
Sponsor
Virginia Commonwealth University
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • Investigational Agent Administration
Locations (sample)
  • Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

  • Patients diagnosed with prostate cancer and treated with androgen deprivation therapy (ADT) and at least one androgen receptor pathway inhibitor (A…
  • Androgen levels ≤50 ng/dL (≤1.73 nmol/L).
  • Disease progression following ADT and ARPI treatment described
  • PSA progression over 2 assessments, defined as rising PSA values from 2 consecutive assessments with an interval of at least 7 days between assessm…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →